Continuous glucose monitoring (CGM) in patients with diabetes using intensive insulin therapy has been well established, but there are limited data for CGM in other diabetes populations. We assessed HbA1c changes following a FreeStyle Libre prescription in people with type 2 diabetes (T2D) with poor glycemic control not using bolus insulin. IBM Explorys, a U.S. electronic health record database, was used in this retrospective, observational study. Cohort requirements included: FreeStyle Libre prescription in 2017 Q4-2020 Q1, de novo to CGM, T2D diagnosis, lack of rapid-/short-acting insulin, age <65 years, baseline HbA1c ≥ 8%, and presence of HbA1c data before and after FreeStyle Libre prescription. Baseline HbA1c was defined as the value within 180 days pre-index closest to CGM prescription date and post-CGM HbA1c as the value closest to 180 days post-index and within 60-300 days after CGM prescription. The outcome of the study was change in HbA1c from baseline to post-FreeStyle Libre prescription. The cohort (n=1,183, age 52 (SD 9.2) years, 52% male) had a reduction in HbA1c from 10.16 (SD 1.75) to 8.78 (SD 1.92) (p<0.001). Those starting with higher HbA1c and those on non-insulin therapy saw the greatest reduction. After receiving a prescription for a FreeStyle Libre system, people with T2D, poor glycemic control, and not using bolus insulin had a significant reduction in HbA1c.


E. Wright: Advisory Panel; Self; Abbott, Sanofi. Consultant; Self; Abbott, AstraZeneca, Bayer U.S., Boehringer Ingelheim Pharmaceuticals, Inc., MannKind Corporation, Merck & Co., Inc., Voluntis France. Speaker’s Bureau; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Lilly Diabetes. M.S.D. Kerr: Employee; Self; Abbott. I.J. Reyes: None. Y. Nabutovsky: Employee; Self; Abbott. E. Miller: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at